Showing results (31-40 of 128) with videos related to
Sort By:
Pageof 13
Clinical Lung Cancer|November 2, 2013
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsDavid R Gandara, Tianhong Li, Primo N Lara, et al.Clinical Lung Cancer|January 15, 2004
Antisense oligonucleotides in the treatment of non-small-cell lung cancerAngela M Davies, David R Gandara, Primo N Lara, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2010
Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancerDavid R Gandara, Peter Grimminger, Philip C Mack, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2011
Aberrant regulation of the MRP3 gene in non-small cell lung carcinomaChristopher M Mahaffey, Nichole C Mahaffey, William Holland, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Predictive molecular markers: has the time come for routine use in lung cancer?Angela M Davies, Philip C Mack, Primo N Lara, et al.Clinical Lung Cancer|March 27, 2007
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategiesDavid R Gandara, Angela M Davies, Oliver Gautschi, et al.The Journal of Thoracic and Cardiovascular Surgery|April 22, 2014
Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancerDavid T Cooke, David R Gandara, Neal C Goodwin, et al.Seminars in Oncology|February 26, 2004
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapyPrimo N Lara, Angela M Davies, Philip C Mack, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trialPrimo N Lara, Philip C Mack, Timothy Synold, et al.Cancer Chemotherapy and Pharmacology|June 7, 2011
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapyWilliam S Holland, Clifford G Tepper, Jose E Pietri, et al.Pageof 13